Wellbutrin XL, a new drug to treat seasonal affective depression (SAD), has got approval from the U.S. Food and Drug Administration. Seasonal affective depression usually strikes in winters. It lasts for six months and shows the symptoms like loss of interest, weight variations, sleep mess, tiredness and suicidal behavior.



FDA has given some guidelines along with the approval of the drug that patients will have to judge the possible threats and advantages when getting the treatment with Wellbutrin XL for seasonal affective depression.



Read